The primary objective of the study is to evaluate the safety of tobevibart+elebsiran in participants with chronic hepatitis Delta virus (HDV) infection. 

The purpose of this study is to learn more about the daily experiences, including thoughts, feelings, social interactions, medication adherence, and overall health and well-being of gay or bisexual men living with HIV ages 45-64.

There are three study visits:

1. Day 1/screening visit
2. 6 month visit
3. 12 month visit.

Participation will last about 12 months. After the Day 1 study visit, participants are asked to complete a daily diary survey and wear a watch that measures sleep and activity for 30 days.  

The purpose of this study is to evaluate a potential long-acting injectable HIV treatment option for people whose HIV is not undetectable.

The study drug is a long-acting HIV treatment. It is given by injection every other month after 2 started doses. This is in contrast to oral ART, which is designed to be taken daily.

This study is comparing rectal and oral Tenofavir-based prep. The rectal study product is a rectal douche, or enema, that contains the anti-HIV drug tenofovir (TFV). The other study product is taken by mouth and is a combination of two drugs, called emtricitabine (FTC or F) and tenofovir disoproxil fumarate (TDF).

Tenofovir (TFV) rectal douche is considered investigational because it is not approved by the U.S. Food and Drug Administration (FDA). Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) is FDA-approved and used according to FDA labeling.

This study examines which patients who have undergone surgical removal of bladder, kidney, ureter or urethra, require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back and if those patients can be identified by a blood test. This study also aims to find out if this approach is better or worse than the usual approach for urothelial cancer.

The purpose of this study is to facilitate the consent, collection, and research use of biospecimens and data for profiling of immune cells and research from patients seen by physicians at Weill Cornell Medical College/New York-Presbyterian who are screened for, consented to, and undergo tumor-infiltrating lymphocyte (TIL) cellular therapy for solid tumor malignancies.
   

This clinical trial is for adults who have congenital antithrombin deficiency (which is a disorder of blood clotting) and who are scheduled to undergo surgery OR childbirth in the near future.
   

 This clinical trial is for adults who have been diagnosed with one of the following relapsed or refractory (R/R) B-cell malignancies: non-germinal center B-cell diffuse large B-cell lymphoma (non-GCB DLBCL), follicular lymphoma (FL), Richter’s Transformation (RT), Waldenstrom macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL).
   

 The purpose of this study is to compare two radiation treatment schedules: one delivers a higher dose of radiation per treatment for fewer treatments over a shorter length of time (SBRT); the other delivers a lower dose of radiation per treatment but for more treatments over a longer time. Short duration radiation therapy instead of the usual treatment could prevent your cancer from coming back.

This study is being done to evaluate if the combination of ASTX727 and venetoclax works better than ASTX727 alone at decreasing the signs and symptoms of bone marrow cancer, known as myelodysplastic/myeloproliferative neoplasm (MDS/MPN).

We are doing this study because we want to find out if this approach is better or worse than the usual approach for bone marrow cancer called chronic myelomonocytic leukemia (CMML) or a less common form called non-CMML MDS/MPN. The usual approach is defined as care most people get.